NCT05317416 (MagnetisMM-7) is a Phase 3 clinical trial of Elranatamab in Multiple Myeloma, sponsored by Pfizer.

Who is sponsoring NCT05317416?

NCT05317416 is sponsored by Pfizer.

What drugs are being tested in NCT05317416?

Interventions in NCT05317416: Elranatamab, Lenalidomide, Lenalidomide, Elranatamab.

What condition does NCT05317416 study?

NCT05317416 studies Multiple Myeloma.

Is NCT05317416 still recruiting?

NCT05317416 is currently active, enrolled. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT05317416: MagnetisMM-7

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Active, enrolled Phase 3 Last updated 16 April 2026

What this trial tests

Phase 3 trial testing Elranatamab in Multiple Myeloma in 854 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

25 March 2022

Primary endpoint
4 August 2027

31 October 2029

Quick facts

Lead sponsor	Pfizer
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	854
Start date	25 March 2022
Primary completion	4 August 2027
Estimated completion	31 October 2029
Sites	209 locations across Italy, Finland, Japan, Taiwan, Poland, South Korea, Netherlands, Belgium

Drugs / interventions tested

Elranatamab (elranatamab) — full drug profile →
Lenalidomide — full drug profile →
Lenalidomide — full drug profile →
Elranatamab (elranatamab) — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

T cells in health and disease.
Sun L, Su Y, Jiao A, Wang X, et al · · 2023 · cited 717× · PMID 37332039 · DOI 10.1038/s41392-023-01471-y
Antibodies to watch in 2023.
Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, et al · · 2023 · cited 204× · PMID 36472472 · DOI 10.1080/19420862.2022.2153410
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
Raje N, Anderson K, Einsele H, Efebera Y, et al · · 2023 · cited 120× · PMID 37528088 · DOI 10.1038/s41408-023-00879-7
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
Leypoldt LB, Tichy D, Besemer B, Hänel M, et al · · 2024 · cited 115× · PMID 37753960 · DOI 10.1200/jco.23.01696
Signaling pathways in the regulation of cancer stem cells and associated targeted therapy.
Manni W, Min W. · · 2022 · cited 52× · PMID 36226253 · DOI 10.1002/mco2.176
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, et al · · 2024 · cited 48× · PMID 38773064 · DOI 10.1038/s41392-024-01826-z
Bispecific antibodies in multiple myeloma treatment: A journey in progress.
Cho SF, Yeh TJ, Anderson KC, Tai YT. · · 2022 · cited 41× · PMID 36330495 · DOI 10.3389/fonc.2022.1032775
Bispecific antibodies in the treatment of multiple myeloma.
Devasia AJ, Chari A, Lancman G. · · 2024 · cited 37× · PMID 39266530 · DOI 10.1038/s41408-024-01139-y

Verify or expand the search:

Other trials of Elranatamab

Trials testing the same drug.

NCT07382739 — A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Mye · Phase 2 · recruiting
NCT07320326 — ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab · not yet recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06997081 — ERd Combination Treatment in Newly Diagnosed Multiple Myeloma · Phase 2 · recruiting
NCT06581848 — Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). · active not recruiting

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05317416 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05317416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing